Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Price Erosion Dents Alembic, Site Re-Inspection Springs Fresh Challenge

Company Remains Bullish Overall On US

Executive Summary

Challenging phase for Alembic as continued price erosion in the US hurts earnings, while a compliance re-inspection by the FDA at an injectables site results in 10 observations. Investors believe US sales may have bottomed out at current levels but can the Indian firm bounce back quickly?

You may also be interested in...



Alembic Suffers 38% Slide In US As Price Erosion Bites

India’s Alembic has reported a 38% drop in its US generics business in the first quarter of its FY22 financial, due to price erosion stemming from increased competition. The company plans to launch four generics in the US in the coming quarter.

Swift And Nimble – Alembic Laps Up US Valsartan Windfall In Q2

Alembic moved fast and seized supply opportunities for valsartan, the hypertension drug that has seen shortages in the US, though management maintains that fundamental changes to the US market are there to stay given the backdrop of buying power of distributors.

Evotec, Takeda Execs’ Big Picture Insights To Shape India’s R&D Push

Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel